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httpcense.Abstract Background: Early detection of malignant pleural mesothelioma (MPM) is critical to
survival, the use of pleural or blood ﬁbuin-3 might allow this early detection.
Aim: Studying the validity of measuring serum and pleural ﬁbulin-3 in the diagnosis of MPM.
Subjects & Methods: Fibulin-3 levels were measured in serum and pleural ﬂuid by enzyme-linked
immunosorbant assay (ELISA) in 45 patients with exudative pleural effusion. Patients with non-
conclusive cytology or microbiological examination had undergone medical thoracosope for histo-
pathological examination.
Results: Twenty ﬁve was diagnosed as MPM, 11 cases as pleural metastasis of carcinoma (Mets)
and nine cases with benign pleural effusions. Patients with MPM had signiﬁcantly higher pleural
effusion and serum ﬁbulin-3 levels than those with metastatic effusion of carcinoma or benign pleu-
ral effusion (p-value <0.001). Using a cut-off point of pleural ﬂuid ﬁbulin-3 (150 ng/ml) with AUC
of 0.878 (sensitivity 72.3%, speciﬁcity 80) and at a cut-off point of serum ﬁbulin-3 (66.5 ng/ml), with
AUC of 0.776 (sensitivity 88%, speciﬁcity 81.8%), discrimination between MPM and Mets
occurred. Also, using a cut-off point of pleural ﬂuid ﬁbulin-3 (127.5 ng/ml) with AUC of 0.909 (sen-
sitivity 88%, speciﬁcity 77.8%), and at a cut-off point of serum ﬁbulin-3 (18 ng/ml), with AUC of
0.931 (sensitivity 100%, speciﬁcity 77.8%), discrimination between MPM and benign pleural effu-
sion could occur.
Conclusions: Fibulin-3 in the serum and pleural ﬂuid is a good biomarker in the diagnosis of
MPM and in differentiation between MPM from malignant pleural metastasis other than mesothe-
lioma and also from benign pleural effusions.
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Malignant pleural effusion is a condition in which cancer
causes an abnormal amount of ﬂuid to collect in the pleural
cavity. Lung cancer and breast cancer account for about
50–65% of malignant pleural effusions. Other common causes
include pleural mesothelioma and lymphoma. Malignant pleu-
ral mesothelioma (MPM) has a very bad prognosis of about ais. Production and hosting by Elsevier B.V.
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100 M.A. Agha et al.year after diagnosis. Earlier detection of this lethal pleural can-
cer could conceivably result in earlier treatment and some
improvement in life [1]. Early detection is limited by the long
latency period, an inability of imaging to detect the disease
at an early stage even when it is used as a screening strategy,
and the lack of sensitive and speciﬁc blood-based markers
[2]. Analysis of pleural ﬂuid yields a conﬁrmed diagnosis in a
relatively small percentage of MPM patients, and needle
biopsy offers only slightly better results. Medical thoracoscopy
is recommended in the investigation of patients with MPM,
which has a diagnostic yield of >95% [3]. Early detection is
critical to survival with mesothelioma, the use of pleural or
blood-based biomarkers might allow detection of MPM at
an early stage. Tumor markers offer an attractive means of
diagnosis, being less expensive and less invasive [4]. Soluble
mesothelin related protein (SMRP), the most extensively stud-
ied blood based mesothelioma biomarker, is limited by an
overall sensitivity of 47% at 96% speciﬁcity [5]. Serum bio-
markers such as SMRp, osteopontin, CA125 and megakaryo-
cyte potentiating factor (MPF) have been investigated as tools
to aid in the diagnosis of malignant mesothelioma, or for
screening of ‘at risk’ group [6]. A positive blood test for mes-
othelin at a high speciﬁcity threshold is a strong incentive for
further diagnostic steps, provided there is no renal failure [7].
However, the poor sensitivity of mesothelin at diagnosis (35–
50%) limits its value. In screening studies, mesothelin levels
are elevated before diagnosis in fewer than 15% of mesotheli-
oma patients in a high risk group, so it is not recommended as
a screening tool [8]. Also osteopontin and CA125 lack speciﬁc-
ity as diagnostic markers, serum mesothelin and CA125 may
have value in monitoring response to treatment [8]. New bio-
markers are needed to detect pleural mesothelioma at an ear-
lier stage. Fibulin-3 is an extracellular glycoprotein in the
ﬁbulin family; these proteins are frequently associated with
vascular and elastic tissues, and become overexpressed in peo-
ple with pleural mesothelioma [9]. Fibulin-3 is a highly con-
served member of the extracellular glycoprotein ﬁbulin
family encoded by the gene epidermal growth factor – contain-
ing ﬁbulin-like extracellular matrix protein 1 (EFEMP1) on
chromosome 2p16 [10]. Gene expression is low in normal tis-
sues, with the highest expression in the thyroid [11]. Fibulin-
3 is expressed in condensing mesenchyme, giving rise to bony
and cartilaginous structures. It mediates cell-to-cell and cell-
to-matrix communication, is inversely related to cell growth,
and has variable angiogenic effects. Inactivation of EFEMP1
due to DNA hypermethylation has been reported in lung,
prostate, colorectal, breast, nasopharyngeal, and hepatocellu-
lar carcinomas [12].
Aim
The aim of this study was to assess the validity of measuring
serum and pleural ﬁbulin-3 in the diagnosis of malignant pleu-
ral mesothelioma and its ability to differentiate between MPM,
and both other pleural malignancies or benign pleural
effusions.
Subjects and methods
Patients with pleural effusion were admitted to the Chest
Department in Menouﬁya University Hospitals, Egypt, duringthe period from January 2013 to August 2013. All patients had
undergone history taking including occupational and environ-
mental hazards, general and local examinations, routine labo-
ratory investigations (Serum lactate dehydrogenase (LDH),
total protein, albumin, liver and kidney functions, ESR and
CBC), Radiological assessment by plain CXR, and CT. Fol-
lowing the previous step, and after the diagnosis of pleural effu-
sion had been conﬁrmed, thoracentesis was done. The routine
study of the pleural ﬂuid included the following: pH, biochem-
ical testing of pleura/serum (LDH, glucose, albumin and Aden-
osine deaminase (ADA), cytology and microbiological testing
(Z–N, L–J culture) and differential cell count). Using Light’s
original criteria (ratio of pleural ﬂuid/serum protein>0.5, ratio
of pleural/serum LDH >0.6 or pleural ﬂuid LDH more than
two-thirds of the upper limit of normal serum value), 20 pa-
tients with transudative pleural effusions were excluded from
the study. The remaining 45 diagnosed to have exudative pleu-
ral effusion was enrolled in the study. Patients with non-conclu-
sive cytology and microbiological examination had undergone
medical thoracosope by which multiple pleural biopsies were
taken and sent for histopathological examination. Tuberculous
pleural effusion was conﬁrmed either by positive Z–N or L–J
culture or by the presence of tuberculous granuloma in the his-
topathological examination. Pleural effusion was categorized
as malignant if pleural ﬂuid cytology or pleural biopsy ﬁndings
were positive for malignancy. A parapneumonic effusion was
the one that developed in a patient with fever, pulmonary inﬁl-
trates and complete response to antibiotic treatment. All other
exudative effusions were included. An idiopathic pleural effu-
sion was identiﬁed as one for which a cause was not determined
despite an initial workup that included repeated thoracenteses
and thoracoscopic pleural biopsies. Patients with transudative
pleural effusion, serious uncontrolled diseases (including renal,
hepatic, cardiac diseases, and coagulopathy), and hemodynam-
ically unstable were excluded.
Collection of blood samples and pleural effusion ﬂuid
Serum: using a serum separator tube and 10 ml of whole blood
samples were allowed to clot for 2 h at room temperature or
overnight at 4 C before centrifugation for 20 min at approxi-
mately 1000g. Assay freshly prepared serum immediately or
store samples in aliquot at 20 C or 80 C for later use. Pleu-
ral ﬂuids: 10 ml of centrifugated samples for 20 min at 1000g
with removal of particulates and assay immediately or samples
were stored in aliquot at 20 C or 80 C for later use.Mea-
surement of ﬁbulin-3: the ﬁbulin-3 concentrations in pleural
ﬂuid and serum were determined using ELISA. The test re-
quired 2–3 h. The assay used two monoclonal antibodies. Dur-
ing incubation, both antibodies reacted with ﬁbulin-3 in a
sandwich-like manner. After several washing procedures, the
tracer remaining in the test tube was measured using a lumino-
meter; the intensity of the luminescent signal was directly pro-
portional to the ﬁbulin-3 concentration of the serum or pleural
ﬂuid sample [13]. All the previous steps were done after a writ-
ten consent from all patients.
Statistical methodology [14]
The data collected were tabulated and analyzed by SPSS
(statistical package for the social science software) statistical
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tive data were expressed as mean and standard deviation
(X± SD). The ANOVA test for analysis of variance (f-test)
was used for comparison of more than two groups of normally
distributed variables and Kruskal–Wallis test was used for
comparison of more than two groups of non-normally distrib-
uted variables. Qualitative data were expressed as number and
percentage (No and %) and analyzed by applying chi-square
test (v2). Pearson correlation (r) was used to detect association
between quantitative variables, while Spearman correlation
was used to detect association between qualitative and quanti-
tative variables. The ROC (receiver operating characteristic)
curve was used to detect the cutoff value with highest sensitiv-
ity and speciﬁcity. Sensitivity, speciﬁcity, positive and negative
predictive value, and diagnostic accuracy were calculated.
All these tests were used as tests of signiﬁcance at p< 0.05.
Results
Forty-ﬁve patients with exudative pleural effusion were in-
cluded in this study after exclusion of 20 cases with transuda-
tive effusion, ﬁve cases refused doing medical thoracoscope, six
cases were unﬁt for doing thoracoscope and three cases died
before completing all steps. By cytopathological examination
of pleural ﬂuid, nine out of the 45 patients (20%) were diag-
nosed. There were two cases of MPM, one case of parapneu-
monic effusion and six cases of pleural metastasis of
carcinoma (Mets) and they did not need to do thoracoscope.
By medical thoracoscopy MPM was diagnosed in 23 of theTable 2 Validity of pleural and serum ﬁbulin-3 in the diagnosis of
MPM METs
Serum ﬁbulin-3 ng/ml 96.64 ± 32.64 58.45 ± 27.01
Pleural ﬁbulin-3 ng/ml 331.88 ± 124.26 153.01 ± 60.32
MPM, malignant pleural mesothelioma; Mets, metastatic pleural maligna
Table 1 Comparison between different groups in the study.
Variables Groups
Malignant pleural
mesothelioma (n= 25)
Metastat
malignan
Mean ± SD Mean ±
Age 52.12 ± 8.09 56.18 ±
Pleural LDH (U/L) 685.16 ± 326.03 406.09 ±
Pleural Total protein (g/dL) 5.65 ± 2.12 4.53 ± 1
Gender
Male 15 (60) 6 (54.5)
Female 10 (40) 5 (45.5)
Smoking (No %)
Yes 16 (64) 6 (54.5)
No 9 (36) 5 (45.5)
Asbestos exposure
No 15 (60) 9 (81.8)
Yes 10 (40) 2 (18.2)
LDH, lactate dehydrogenase. *ANOVA, ** Kruskal–Wallis test; SD, s
difference.45 cases, while of the remaining 13 cases; ﬁve cases were diag-
nosed as malignant pleural disease other than MPM, ﬁve cases
with tuberculous pleuritis, and the remaining three cases were
diagnosed as non-speciﬁc inﬂammation. The ﬁnal diagnoses
were classiﬁed into three groups: 25 cases of MPM (their
histological subtypes were 10 epitheliod, six sarcomatoid and
nine biphasic subtypes, 11 cases of pleural metastases of carci-
nomas (three cases of non small cell lung cancer, two cases of
breast cancer, three cancer colon, one case renal cancer and
two cases of lymphoma) and nine patients with non malignant
pleural effusion (ﬁve tuberculous cases), one parapneumonic
effusion, and three cases with non-speciﬁc inﬂammation (one
case discharged on anti TB treatment because of the elevated
ESR and ADA levels and the 2nd case referred to the cardio-
thoracic department where surgical thoracoscope was done
where TB granuloma was conﬁrmed, while the last one was
idiopathic effusion). Table 1 shows that there was no signiﬁ-
cant difference in the studied groups as regard age, gender,
smoking habits and asbestos exposure, while the difference
in pleural LDH and the total protein was signiﬁcant. Patients
with MPM had signiﬁcantly higher pleural effusion and serum
ﬁbulin-3 levels (331 ± 32.64 and 96.64 ± 32.64 ng/ml, respec-
tively) than those with metastatic effusion of carcinoma
(153.01 ± 60.32 and 58.45 ± 27.01 ng/ml, respectively) or be-
nign pleural effusion (84.884 ± 83.38 and 30.11 ± 33.72 ng/
ml, respectively) and these levels were highly signiﬁcant differ-
ence (p-value <0.001). (Table 2). There was no signiﬁcant dif-
ference between mean values of the pleural and serum ﬁbulin-3
regarding the three pathological types of the malignant pleuralmalignant pleural diseases.
Benign pleural eﬀusion Kruskal–Wallis test
30.11 ± 33.72 18.64 <0.001HS
84.88 ± 83.38 21.43 <0.001HS
ncy; ng/ml, nanogram/milliliter; HS, highly signiﬁcant difference.
Chi square p-Value
ic pleural
cy (n= 11)
Benign pleural
eﬀusion (n= 9)
SD Mean ± SD
9.41 46.88 ± 8.02 3.02* 0.059
158.12 216.56 ± 35.47 24.71** <0.001HS
.16 3.16 ± 0.73 12.34* 0.002S*
5 (55.6) 0.116 0.944
4 (44.4)
3 (33.3) 2.52 0.283
6 (66.7)
9 (100) 5.95 0.051
0 (0)
tandard deviation. S*, signiﬁcant difference; HS, highly signiﬁcant
Table 3 Validity of serum and pleural ﬁebulin-3 in the differentiation between different pathological types of malignant pleural
mesothelioma.
Variables MPM-E MPM-S MPM-B ANOVA p-Value
Mean ± SD Mean ± SD Mean ± SD
Serum ﬁbulin-3 95.17 ± 36.09 95.80 ± 33.56 98.55 ± 32.64 0.023 >0.05
Pleural ﬁbulin-3 330.17 ± 159.31 324.10 ± 119.02 341.67 ± 119.74 0.044 >0.05
MPM, malignant pleural mesothelioma; E, epitheliod; S, sarcomatoid; B, biphasic; SD, standard deviation.
Table 4 Validity of ﬁbulin-3 for the diagnosis of the malig-
nant cases regarding benign lesions.
Serum ﬁbulin-3 Pleural ﬁbulin-3
Cut oﬀ point 18 76.5
Sensitivity (%) 100 91.7
Speciﬁcity (%) 77.8 77.8
PPV (%) 95 94
NPV (%) 100 70
Accuracy (%) 96 89
AUC 0.897 0.878
ROC, receiver operating characteristic; AUC, area under the curve;
PPV, positive predictive value; NPV, negative predictive value.
Figure 1 ROC curve for the malignant cases regarding benign
lesions.
Table 5 Validity of ﬁbulin-3 in the differentiation of meso-
thelioma lesions regarding pleural malignancies.
Serum ﬁbulin-3 Pleural ﬁbulin-3
Cut oﬀ point 66.5 150
Sensitivity (%) 88 72.3
Speciﬁcity (%) 81.8 80
PPV (%) 92 73
NPV (%) 75 88
Accuracy (%) 86 83
AUC 0.776 0.878
ROC, receiver operating characteristic; AUC, area under the curve;
PPV, positive predictive value; NPV, negative predictive value.
Figure 2 ROC curve for the mesothelioma lesions with other
malignancies.
102 M.A. Agha et al.mesothelioma (p-value >0.05). (Table 3), Table 4 and Fig. 1
show that using a cut-off point of pleural ﬂuid ﬁbulin-3
(76.5 ng/ml) with AUC of 0.878 (sensitivity 91.7%, speciﬁcity
77.8%, NPV 70%, PPV 94% and accuracy 89%) and at a
cut-off point of serum febulin-3 (18 ng/ml), with AUC of
0.897 (sensitivity 100%, speciﬁcity 77.8%, NPV 100%, PPV95% and accuracy 96%) discrimination between malignant
and benign pleural effusion occurred. While using a cut-off
point of pleural ﬂuid ﬁbulin-3 (150 ng/ml) with AUC of
0.878 (sensitivity 72.3%, speciﬁcity 80%, NPV 88%, PPV
73% and accuracy 83%) and at a cut-off point of serum
ﬁbulin-3 (66.5 ng/ml), with AUC of 0.776 (sensitivity 88%,
Table 6 Validity of ﬁbulin-3 in detecting mesothelioma
lesions regarding benign lesions.
Serum ﬁbulin-3 Pleural ﬁbulin-3
Cut oﬀ point 18 127.5
Sensitivity (%) 100 88
Speciﬁcity (%) 77.8 77.8
PPV (%) 93 92
NPV (%) 100 70
Accuracy (%) 94 85
Area under the curve 0.931 0.909
ROC, receiver operating characteristic; AUC, area under the curve;
PPV, positive predictive value; NPV, negative predictive value.
Figure 3 ROC curve for the mesothelioma lesions with benign
lesions.
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discrimination between MPM and Mets occurred. (Table 5
and Fig. 2) Also, using a cut-off point of pleural ﬂuid ﬁbu-
lin-3 (127.5 ng/ml) with AUC of 0.909 (sensitivity 88%, speci-
ﬁcity 77.8%, NPV 70%, PPV 92% and accuracy 85%) and at a
cut-off point of serum ﬁbulin-3 (18 ng/ml), with AUC of 0.931
(sensitivity 100%, speciﬁcity 77.8%, NPV 100%, PPV 93%
and accuracy 94%) discrimination between MPM and benign
pleural effusion could occur (Table 6 and Fig. 3). While Fig. 4
shows that there was a positive correlation between values of
serum and pleural ﬁbulin-3 in the diagnosis MPM.
Discussion
Malignant pleural mesothelioma has a very bad prognosis of
about a year after diagnosis. Earlier detection of this lethal
pleural cancer could conceivably result in earlier treatment
and some improvement in life [1]. Early detection is limitedby the long latency period, an inability of imaging to detect
the disease at an early stage even when it is used as a screening
strategy, and the lack of sensitive and speciﬁc blood-based
markers [2]. The aim of this work was to assess the ability of
serum and pleural ﬁbulin-3 to aid in the early diagnosis of
MPM and its ability to differentiate between malignant and
non malignant pleural effusions. In our study, the mean age
of the patients with MPM was 52.12 years with a male to
female ratio 1.5:1. These results are in accordance with those
of the study of Hoda et al. [15] who found that, the mean
age of patients was 47.2 years and ranging from 20 to 80 years
with a male to female ratio 1.5:1. And also the results obtained
by El-Shaﬁey [16] recorded a mean age of 47.4 years ranging
from 17–85 years and M:F ratio 1.7:1, as well as the results ob-
tained by Abou Elkasem [17] recorded a median age of
46 years and M:F ratio 1.4:1. In Western studies, the recorded
median age was so much higher ranging from 60 to 69 years
and M:F ratio higher than 10 [18–20]. The ﬁgures obtained
by our study could be explained by the chance of exposure
among both sexes which is nearly equal with a slight increase
in males due to their outdoor activities most of the time in
the vicinity of the asbestos plants and due to occupational haz-
ards. According to the histopathologic type, most of our cases
were of the epitheliod type (40%) followed by biphasic type
(36%) and the lowest incidence type was the sarcomatoid
(24%). Our results are in agreement with that of Hoda et al.
[15] who found that the commonest type was the epitheliod
(50.8%), followed by the mixed type (34.4%) and the sarcoma-
toid type (14.8%). These results lie in accordance with other
studies reporting highest frequency for epitheliod type and
lowest for sarcomatoid type [18,21,22]. In the present work
10 (40%) of the 25 cases with malignant pleural mesothelioma
was asbestos exposed although there was nonstatistically sig-
niﬁcant difference (p-value >0.05). These results are not in
accordance with most of the studies that put the asbestos expo-
suring as the main risk factor of malignant pleural mesotheli-
oma [23–27]. Our low incidence may be due to the small
number of the studied samples, also, most of the studies con-
centrated in the incidence of MPM in areas with endemic
asbestos exposure. The results of the present study conﬁrmed
the role of measuring pleural and serum ﬁbulin-3 in the diag-
nosis of malignant pleural mesothelioma and in differentiation
between MPM and both other pleural malignant metastasis or
benign pleural effusion. Our results showed that the values of
pleural and serum ﬁbulin-3 (331 ± 32.64 and 96.64 ±
32.64 ng/ml, respectively) were signiﬁcantly higher than those
with metastatic effusion of carcinoma (153.01 ± 60.32 and
58.45 ± 27.01 ng/ml, respectively) and benign pleural effusion
(84.884 ± 83.38 and 30.11 ± 33.72 ng/ml, respectively). The
previous ﬁndings are in agreement with the study of Pass
et al. [28] who measured ﬁbulin-3 levels in plasma (from 92
patients with mesothelioma, 136 asbestos-exposed persons
without cancer, 93 patients with effusions not due to mesothe-
lioma, and 43 healthy controls), effusions (from 74 patients
with mesothelioma, 39 with benign effusions, and 54 with
malignant effusions not due to mesothelioma), or both. Pass
et al. [28] found that plasma ﬁbulin-3 levels did not vary
according to age, sex, duration of asbestos exposure, or degree
of radiographic changes and were signiﬁcantly higher in pa-
tients with pleural mesothelioma (105 ± 7 ng/ml in the Detroit
cohort and 113 ± 8 ng/ml in the New York cohort) than in
asbestos-exposed persons without mesothelioma (14 ± 1 ng/
Figure 4 Correlation between pleural and serum ﬁbulin-3.
104 M.A. Agha et al.ml and 24 ± 1 ng/ml, respectively; p< 0.001). Effusion ﬁbu-
lin-3 levels were signiﬁcantly higher in patients with pleural
mesothelioma (694 ± 37 ng/ml in the Detroit cohort and
636 ± 92 ng/ml in the New York cohort) than in patients with
effusions not due to mesothelioma (212 ± 25 and
151 ± 23 ng/ml, respectively; P< 0.001). The present work
showed that using a cut-off point of pleural ﬂuid febulin-3
(76.5 ng/ml) with AUC of 0.878 (sensitivity 91.7%, speciﬁcity
77.8%, NPV 70%, PPV 94% and accuracy 89%) and at a
cut-off point of serum ﬁbulin-3 (18 ng/ml), with AUC of
0.897 (sensitivity 100%, speciﬁcity 77.8%, NPV 100%, PPV
95% and accuracy 96%) discrimination between malignant
and benign pleural effusion occurred. While using a cut-off
point of pleural ﬂuid ﬁbulin-3 (150 ng/ml) with AUC of
0.878 (sensitivity 72.3%, speciﬁcity 80%, NPV 88%, PPV
73% and accuracy 83%) and at a cut-off point of serum ﬁbu-
lin-3 (66.5 ng/ml), with AUC of 0.776 (sensitivity 88%, speci-
ﬁcity 81.8%, NPV 75%, PPV 92% and accuracy 86%)
discrimination between MPM and Mets occurred. Also, using
a cut-off point of pleural ﬂuid ﬁbulin-3 (127.5 ng/ml) with
AUC of 0.909 (sensitivity 88%, speciﬁcity 77.8%, NPV 70%,
PPV 92% and accuracy 85%) and at a cut-off point of serum
ﬁbulin-3 (18 ng/ml), with AUC of 0.931 (sensitivity 100%,
speciﬁcity 77.8%, NPV 100%, PPV 93% and accuracy 94%)
discrimination between MPM and benign pleural effusion
could occur. Pass et al. [28] found that ﬁbulin-3 levels in effu-
sions discriminated between patients with mesothelioma and
participants without the condition in both the Detroit and
New York cohorts, with AUCs of 0.95 and 0.91, respectively,
and the cutoffs for maximum sensitivity and speciﬁcity were
similar (378 ng/ml and 346 ng/ml). Also, ﬁbulin-3 levels dis-
criminated patients with MPM from patients with any other
type of effusions (AUC, 0.93), whether they had benign effu-
sions (AUC, 0.93) or malignant effusions (AUC, 0.94). Alsotheir results showed that a cutoff value of 32.9 ng/ml had the
highest accuracy (minimal false negative and false positive re-
sults) for mesothelioma detection (sensitivity 100%, speciﬁcity
100%). These data were independently conﬁrmed in the New
York cohort, with an AUC of 0.99 at a cutoff level of
52.8 ng/ml for the highest accuracy (sensitivity 94.6%, speciﬁc-
ity 95.7%). When the Detroit and New York cohorts were
combined, the AUC was 0.99 at a cutoff level of 52.8 ng/ml
for the highest accuracy in a comparison to plasma samples
from 92 patients with mesothelioma with plasma samples from
all 290 controls. The present study is in agreement with that of
Pass et al. [28], in conﬁrming the role of serum and pleural feb-
ulin-3 in the diagnosis of malignant pleural mesothelioma and
in differentiating between malignant and benign pleural dis-
eases but the study of Pass conﬁrmed the role of ﬁbulin-3 in
early detection and identiﬁcation of risky patients as the stud-
ied asbestos exposed non malignant subjects and found in-
creased levels of serum and pleural febulin-3. Also our
results showed correlation between serum and pleural febu-
lin-3 levels while surprisingly, Pass et al., found that effusion
ﬁbulin-3 levels did not correlate with plasma levels and they
found no explanation for this result.
Conclusions
Fibulin-3 is a good biomarker in the serum and pleural ﬂuid
for the diagnosis of malignant pleural mesothelioma. Also,
pleural and serum febulin-3 can differentiate between MPM
and either pleural metastasis of carcinoma or benign pleural
effusions. More studies comparing febulin-3 with other com-
mon biomarkers for MPM should be done for conﬁrming feb-
ulin-3 role in the diagnosis, also, studying its role in
monitoring treatment and in evaluating the prognosis of the
disease.
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